Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Jan Molenaar

Principal Investigator
Jan Molenaar
Jan Molenaar
Prof. dr. Jan Molenaar leads a research group in the Princess Máxima Center, which focuses on precision medicine in pediatric cancer.
Phone +31 6 18051678
  • MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

    • jan. 2023
    • Thomas F, Eleveld, et al
    • Frontiers in Oncology
  • Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

    • dec. 2022
    • Mareike, Berlak, et al
    • Molecular cancer
  • Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch

    • dec. 2022
    • Annelisa M, Cornel, et al
    • Journal for ImmunoTherapy of Cancer
  • Implementation of paediatric precision oncology into clinical practice

    • nov. 2022
    • Karin P.S., Langenberg, et al
    • European Journal of Cancer
  • Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma

    • sep. 2022
    • Kaylee M., Keller, et al
    • Frontiers in Oncology
View all publications